Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib
Status:
Terminated
Trial end date:
2020-10-06
Target enrollment:
Participant gender:
Summary
Finding the balance between toxicity and benefit should be the major goal when negotiating
about the therapeutic regimen. This becomes nowadays even more important, since there are
emerging options in the field of sarcoma therapy. Especially in the palliative treatment of
sarcoma patients, knowing that na single drug can provide an overall survival benefit,
physicians have to incorporate the patient's preferences and goals in life when consulting
them.
The study will allow patients with several types of soff tissue sarcoma to be included. After
progression under current therapy, the patient will be randomized in a 1:1 fashion and
allocated to either pazopanib or investigator's choice. Quality of life (QoL) and other
secondary outcome measures will be recorded continuously. The aim of the study is to assess
patient reported outcomes (PROs), which should be the primary aim when treating these
patients.